Clinical trials: Immune System Disease
Mycosis Fungoides, Sezary Syndrome
Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary Syndrome
The purpose of this study is to determine the efficacy of the drug, HuMax-CD4, in patients with mycosis fungoides(MF) and sezary syndrome who are intolerant to or do not respond to treatment with Targretin® and one other standard…
- Trial name
- NCT00127881
- Testing
- HuMax-CD4 (zanolimumab)
- Where
- 35 sites in United States, France and 3 more
- Volunteers
- 76 people
- Sponsor
- Emergent Product Development Seattle LLC
Chronic Idiopathic Urticaria
A Study to Evaluate the Efficacy, Response Duration and Safety of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine Treatment (H1)
The study is a global Phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of omalizumab administered subcutaneously as an add-on therapy for the treatment…
- Trial name
- NCT01292473
- Testing
- Omalizumab
- Where
- 61 sites in United States, Denmark and 6 more
- Volunteers
- 323 people
- Sponsor
- Genentech, Inc.
Chronic Lymphocytic Leukemia
MEOI and HRQoL in CLL Patients Treated With BTKis
This is a multi-site observational study of medical events of interest (MEOI) and health-related quality of life (HRQoL) in chronic lymphocytic leukemia (CLL) patients initiating treatment with the Bruton's tyrosine kinase…
- Trial name
- NCT04938141
- Where
- 16 sites in United States
- Volunteers
- 23 people
- Sponsor
- AstraZeneca
Human Immunodeficiency Virus
Study in HIV1-Positive, Virosuppressed Patients Currently inTreatment With Ritonavir-Boosted Protease Inhibitors (PI/r) Starting Cobicistat-Boosted Darunavir (DRV/c - Rezolsta)
The purpose of this study is to describe the effectiveness of darunavir/cobicistat (DRV/c)-based regimens, measured as maintenance of virological suppression 48 weeks after baseline, defined as the day when the treatment with…
- Trial name
- STORE (NCT02926456)
- Volunteers
- 337 people
- Sponsor
- Janssen-Cilag S.p.A.
Autoimmune Encephalitis, Early-stage Panencephalitis
Monitoring of Outcomes of Cellular and Exosome-based Therapies in Autoinflammatory and Post-infectious Neuroinflammatory Syndromes
This is a prospective, non-randomized, observational registry study evaluating the clinical outcomes of patients with autoimmune or post-infectious neuroinflammatory syndromes receiving stem cell-derived biologics (including…
- Conditions
- Autoimmune Encephalitis, Early-stage Panencephalitis, Neuroinflammatory Demyelination
- Trial name
- NCT07145502
- Testing
- Allogeneic MSC infusions (IV)
- Where
- Poland
- Volunteers
- 76 people
- Sponsor
- Biocells Medical
Asthma
Influence Of Different Airflow Resistances On Drug Effect Of 50μg Salmeterol And 6 μg Formoterol
Effect of inhaled drugs administered as dry powder is not only dependent on drug efficacy but also on technical properties of the inhalers.
- Trial name
- NCT00327353
- Testing
- formoterol (TURBOHALER), Salmeterol (DISKUS)
- Where
- 2 sites in Germany
- Volunteers
- 77 people
- Sponsor
- GlaxoSmithKline
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Mantle Cell Lymphoma
Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment
The primary objective of this study is to evaluate the safety of zanubrutinib (also known as BGB-3111) in chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenström macroglobulinemia, mantle cell lymphoma, or marginal…
- Conditions
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia
- Trial name
- NCT04116437
- Testing
- Zanubrutinib
- Where
- 24 sites in United States
- Volunteers
- 96 people
- Sponsor
- BeiGene
Multiple Sclerosis
BENEFIT Extension Study
To assess the long-term effects of early therapeutic intervention, i.e. within two years following a first clinical demyelinating event suggestive of MS.
- Trial name
- NCT00544037
- Testing
- Interferon beta-1b (Betaseron, BAY86-5046)
- Where
- 18 sites in Austria, Belgium and 16 more
- Volunteers
- 283 people
- Sponsor
- Bayer
Arthritis, Rheumatoid
Observational Study of Meloxicam in Any Labeled Indication
Evaluation on the amelioration of symptom intensity of the indication and to evaluate drug tolerability.
- Trial name
- NCT02182739
- Testing
- Meloxicam
- Volunteers
- 13,039 people
- Sponsor
- Boehringer Ingelheim
Multiple Myeloma
Elranatamab Expanded Access Protocol in Adults With Relapsed/Refractory Multiple Myeloma
Elranatamab is a bispecific antibody: binding of elranatamab to CD3- expressing T-cell and BCMA- expressing multiple myeloma cells causes targeted T-cell mediated cytotoxicity.
- Trial name
- MAGNETISMM17 (NCT05462639)
- Testing
- Elranatamab (PF-06863135)
- Where
- 36 sites in United States, Canada
- Sponsor
- Pfizer
Atopic Dermatitis
Safety and Efficacy of FURESTEM-AD Inj. in Patients With Moderately Subacute and Chronic Atopic Dermatitis (AD)
The purpose of phase I clinical trial is to evaluate safety and efficacy in subjects with over Moderately subacute and chronic Atopic Dermatitis after inject.
- Trial name
- NCT01927705
- Testing
- FURESTEM-AD Inj.
- Where
- South Korea
- Volunteers
- 34 people
- Sponsor
- Kang Stem Biotech Co., Ltd.
Rheumatoid Arthritis
Development of a Normative Database for Rheumatoid Arthritis (RA) Imaging With Tc99m Tilmanocept
This study will establish a normative database of Tilmanocept Uptake Values (TUVjoint) in healthy controls age-matched to the RA population.
- Trial name
- NCT04947137
- Testing
- Tc99m tilmanocept
- Where
- 7 sites in United States
- Volunteers
- 134 people, healthy volunteers welcome
- Sponsor
- Navidea Biopharmaceuticals
Asthma
Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent® HFA 110 mcg
A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent® HFA 110 mcg, in…
- Trial name
- NCT03879837
- Testing
- Fluticasone propionate pressurized metered dose inhaler, Flovent HFA pressurized metered dose inhaler
- Where
- United States
- Volunteers
- 1,902 people
- Sponsor
- Actavis Inc.
Dermatitis, Atopic
Long-Term Follow-up Study of FURESTEM-AD in Patients With Atopic Dermatitis(K0106)
Long-Term Follow-up Study of Subjects With Moderate to Severe Chronic Atopic Dermatitis Who Had Administered FURESTEM-AD Inj. in K0106 Study
- Trial name
- NCT07582237
- Where
- South Korea
- Volunteers
- 262 people
- Sponsor
- Kang Stem Biotech Co., Ltd.
Multiple Myeloma
Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma
The purpose of this study is to evaluate time to progression, overall survival, response rate and safety for the two open-label treatment groups; DOXIL/CAELYX in combination with VELCADE vs. VELCADE monotherapy.
- Trial name
- NCT00103506
- Testing
- Bortezomib (VELCADE), Doxorubicin hydrochloride (DOXIL/CAELYX)
- Where
- 108 sites in United States, Argentina and 15 more
- Volunteers
- 646 people
- Sponsor
- Janssen Research & Development, LLC
Allergy
Cetirizine Chewable Bioequivalence and Food Effect Study
The purpose of this study is to determine and compare the amount of study drug that gets into your blood after the administration of each of the three formulations of cetirizine under different conditions.
- Trial name
- NCT03772158
- Testing
- Cetirizine 10mg, Cetirizine 10 mg
- Where
- Canada
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division
Autoimmune Encephalitis Caused by N-Methyl D-Aspartate Receptor Antibody, Autoimmune Encephalitis Caused by N-Methyl D-Aspartate Receptor Antibody (Disorder)
Phase 1 Study of ART5803 Safety and PK After IVIG in Healthy Participants
This study will evaluate the safety, tolerability, and pharmacokinetics (PK) of ART5803 following IVIG administration in healthy participants to investigate the potential interactions between ART5803 and IVIG
- Conditions
- Autoimmune Encephalitis Caused by N-Methyl D-Aspartate Receptor Antibody, Autoimmune Encephalitis Caused by N-Methyl D-Aspartate Receptor Antibody (Disorder), Autoimmune Encephalitis
- Trial name
- NCT06753955
- Testing
- ART5803, Intravenous immunoglobulin (IVIG)
- Where
- Australia
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Arialys Therapeutics
Malnutrition, Cancer
Impact of a New Plant-based High-energy Oral Nutritional Supplement on Nutritional Outcomes in Malnourished Patients
This study aims to compare nutritional outcomes in terms of percentage of weight gain between a new planted-based high-energy ONS and a standard high-energy ONS with animal protein (cow's mil protein) in patients at malnutrition…
- Conditions
- Malnutrition, Cancer, Inflammatory Bowel Diseases, Chronic Obstructive Pulmonary Disease (COPD)
- Trial name
- NCT06055543
- Testing
- Fortimel
- Where
- 6 sites in Spain
- Volunteers
- 140 people
- Sponsor
- Danone Specialized Nutrition
Dermatitis, Atopic
Distribution of Tacrolimus in Skin, Atopic Dermatitis
This study was designed to further increase the understanding of the pharmacokinetics of tacrolimus in the affected skin of atopic dermatitis patients following repeated topical application of tacrolimus ointment 0.1%.
- Trial name
- NCT00534508
- Testing
- Tacrolimus Ointment 0.1%
- Where
- Ireland
- Volunteers
- 14 people
- Sponsor
- Astellas Pharma Inc
Conjunctivitis, Allergic
A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis
This study will evaluate the duration of action of LASTACAFT® and Pataday™ as compared to artificial tears (placebo) in the prevention of ocular itching associated with allergic conjunctivitis.
- Trial name
- NCT01470118
- Testing
- alcaftadine 0.25% ophthalmic solution, olopatadine 0.2% ophthalmic solution, dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
- Where
- United States
- Volunteers
- 127 people
- Sponsor
- Allergan
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.